News
FDA Grants Accelerated Approval to Avutometinib–Defactinib Combo for KRAS-Mutant Ovarian Cancer
Pune, India | August 21, 2025 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new targeted treatment that combines avutometinib
Read More